Total trials
57
Active
18
Phase 3
1
Total enrollment
20,434
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ceftazidime | — | — | — | — | — | 1 | |
| Ciprofloxacin | — | — | — | — | — | 1 | |
| Levofloxacin | — | — | — | — | — | 1 | |
| Curcuminoid Standardized Turmeric | — | — | — | — | — | 1 |
Next readouts
- 2025-09-30
- 2025-11-30
- 2026-07-31
Top conditions
- HIV/AIDS2
- Depression in Adults2
- Smoking Cessation2
- Blood Pressure2
- Pregnancy Related2
- Neutropenic Fever2
- Acute Lymphoblastic Leukemia2
- Coronavirus Infections1
Frequently asked questions about Gadjah Mada University
- How many clinical trials does Gadjah Mada University have on ClinicalTrials.gov?
- Gadjah Mada University is listed as the lead sponsor on 57 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gadjah Mada University's trials are in Phase 3?
- 1 of Gadjah Mada University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Gadjah Mada University focus on?
- Gadjah Mada University's most-studied conditions on ClinicalTrials.gov are HIV/AIDS, Depression in Adults, Smoking Cessation, Blood Pressure, Pregnancy Related.
- When are Gadjah Mada University's next clinical trial readouts?
- Gadjah Mada University has 3 upcoming primary-completion readouts tracked here; the soonest is “Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu”, expected around 2025-09-30.